search
EN
中
Current Location：Home About QyunsCompany Profile

Company Profile

Adhering to the vision of "innovation for the great majority", Qyuns Therapeutics (2509.HK) focuses on R & D, industrialization and commercialization of antibody drugs for autoimmune and allergic diseases, and strives to improve drug accessibility and affordability.

Based on our independent innovation capabilities, the company has built a comprehensive pipeline, including 1 product with BLA acceptance, 2 products at phase III clinical stage, 4 products at phase II or phase I, with indications covering the four major disease areas of skin, respiratory, digestive, and rheumatism. We are one of those who received the most IND approvals regarding autoimmune and allergic diseases in China.

Qyuns Therapeutics, as a national high-tech enterprise, has applied for more than 90 invention patents domestic and overseas. It has also been recognized as a potential unicorn enterprise by Productivity Centre of Jiangsu Province.


Mission

“ To pursue scientific innovation and deliver affordable and quality therapeutics ”

To achieve this mission, Qyuns continues to advance its research and development process and expand its product pipeline through independent innovation, forward-looking industrial input, and diversified collaboration. To make innovation sustainable, make patients affordable, and make drugs more accessible!

Advantages and Strategies

Our Strengths
01
Exclusive focus on autoimmune and allergic diseases, with comprehensive coverage of four major disease areas and deep knowledge of key therapeutic pathways;
02
Broad pipeline of biologics in autoimmune and allergic diseases, with Core Products in late-stage clinical development for the most advanced indications
03
Commercial-scale in-house manufacturing capacity ensuring stable and costcontrollable supply of our products;
04
Practical commercialization model leveraging strategic partnership to secure early product launch;
05
A visionary management team with rich industry experience and successful entrepreneurial track records.
Our Strategy
01
Build leadership in dermatology, advance other drug candidates and strategically expand our pipeline;
02
Continue to optimize CMC quality management system and improve production efficiency and enhance manufacturing capacity utilization;
03
Collaborate with potential partners in commercialization;
04
Explore international expansion opportunities;
05
Continue to recruit and develop talent.

Company History

Never stop on innovation and exploration
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2016
  • 2015

  • Entered into a collaboration agreement with Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma) with respect to the development , manufacturing and commercialization of QX004N

    Qyuns Successfully Listed on the Main Board of SEHK

    Entered into a collaboration agreement with Joincare Pharmaceutical Group Industry Co., Ltd. (“Joincare”) with respect to the development and commercialization of QX008N

    Received the breakthrough therapy designation for QX005N for the treatment of PN from the CDE

  • Completed Phase III clinical trial for QX001S for the treatment of Ps and BLA accepted

    Completed Phase II clinical trial for QX002N for the treatment of AS and Initiated Phase III clinical trial for QX002N for the treatment of AS

    Initiated Phase II clinical trial for QX005N for the treatment of PN and CRSwNP

    Initiated Phase II clinical trial for QX004N for the treatment of Ps

    Received IND approvals from the NMPA for QX005N for the treatment of COPD and adolescent AD

    Built joint laboratory with China Pharmaceutical University.

    Awarded as a potential unicorn enterprise in Jiangsu Province for four consecutive years

    Won awards from multiple authoritative institutions

  • Won awards from multiple authoritative institutions in the industry.

    Awarded as a potential unicorn enterprise in Jiangsu Province for three consecutive years.

    The Phase III clinical trial of QX001S for the treatment of Ps in China reached its primary endpoint.

    Initiated the Phase II clinical trial of QX002N for the treatment of AS in China and completed patient enrollment.

    Received an IND approval from FDA for QX008N for the treatment of severe asthma.

    Received IND approval from the NMPA for QX008N for the treatment of asthma and for the treatment of moderate-to-severe COPD.

    Received IND approvals from the NMPA for QX005N for the treatment of CSU, the treatment of PN and the treatment of moderate-to-severe asthma.

    Received IND approval from NMPA for QX004 for the treatment of Crohn’s disease.

    Obtained National High tech Enterprise Certificate.

    Closed series C round funding and raised RMB227.5 million.

    Approved to build Jiangsu Provincial Immune Disease Antibody Engineering Research Cente.

  • Completion of shareholding system reform.

    Received IND approval from the NMPA for QX005N for the treatment of CRSwNP.

    Received IND approval from the NMPA for QX006N for the treatment of SLE.

    Received IND approval from the NMPA for QX004N for the treatment of Ps.

    Completed the Phase Ia clinical trial of QX002N for the treatment of AS in China.

    Closed series B++ round funding and raised RMB300 million.

  • Closed series B+ round funding and raised RMB370 million.

    Entered into a collaboration agreement with Zhongmei Huadong with respect to the joint development and commercialization of QX001S in China.

    Closed series B round financing and raised RMB230 million.

    Received IND approval of QX005N from the NMPA for the treatment of moderate-to-severe AD in adults in China.

    Completed the Phase I clinical trial of QX001S for the treatment of Ps in China.

  • Received IND approval of QX002N from the NMPA for the treatment of active AS in adults in China.

  • Cellularforce, our CMC-focused subsidiary, was established in Taizhou.

    Received IND approval of QX001S from the NMPA for the treatment of moderate-to-severe plaque Ps in China.

  • Closed series A round financing and raised RMB120 million.

  • Closed series Pre-A round financing and raised RMB14 million.

    Founded in China Medical City (Taizhou).